MIAMI, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Captivision Inc. (“Captivision” or the “Company”) (Nasdaq: CAPT), a pioneering manufacturer and global LED provider, announced continuing strategic transformation and a resulting management change in preparation. As previously announced, the Company is exploring strategic options for Captivision Korea, its wholly owned subsidiary. This exploration has extended to Captivision Inc. with options within the LED industry broadly defined and beyond, continuing to optimize ...

SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 12:55 p.m. ET. Live webcasts and recordings of these presentations will be availa ...

PRELIMINARY PROSPECTUS ACCESSIBLE ON SEDAR+ NOT FOR RELEASE OR DISTRIBUTION IN THE UNITED STATES OR FOR DISSEMINATION TO U.S. NEWS WIRE SERVICES TORONTO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, announced today that it has filed a preliminary short form prospectus (the “P ...

Core Insights - Teva Pharmaceutical Industries Ltd. will present at three investor conferences in December 2025, featuring CEO Richard Francis and other executive management [1][5] - The company is transitioning into a leading innovative biopharmaceutical firm, supported by a strong generics business, with a focus on neuroscience, immunology, complex generics, biosimilars, and pharmacy brands [3] Company Overview - Teva has been committed to improving health for over 120 years, emphasizing innovation and addressing patient needs [3] - The company aims to expand its innovative and biosimilar medicines pipeline while maintaining its generic medicines portfolio [4]

Core Points - Opendoor Technologies Inc. announced the distribution of warrants to purchase common stock to registered stockholders and certain convertible noteholders on November 21, 2025, as part of a special dividend [1][2] - Each stockholder of record as of November 18, 2025, received three series of warrants (Series K, Series A, and Series Z) at a ratio of one warrant per thirty shares held [1][3] - The CEO emphasized that this warrant dividend reflects confidence in the company's business and aims to strengthen the relationship with shareholders [2] Warrant Terms - Eligibility for receiving warrants is based on being a shareholder of record as of the Record Date, November 18, 2025 [3] - The distribution ratio is one warrant of each series for every thirty shares held, with no fractional warrants issued [3] - Exercise prices are set at $9.00 for Series K, $13.00 for Series A, and $17.00 for Series Z [3] - The warrants are exercisable for cash, with a potential for net exercise as per the warrant agreement [3] - Each series of warrants will expire on November 20, 2026, unless the Early Expiration Price Condition is met [3] - The Early Expiration Price Condition requires the daily volume-weighted average price of the common stock to meet or exceed specified trigger prices for each series [3] Additional Information - Shareholders are encouraged to review the company's Investor Relations Resource Page for more information [4] - The warrants are expected to trade on Nasdaq under the tickers OPENW (Series K), OPENL (Series A), and OPENZ (Series Z) [7] - Convertible noteholders of the 7.000% Convertible Senior Notes due 2030 received warrants on the same terms as common stockholders [7]

NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Figure Technology Solutions, Inc. (Nasdaq: FIGR), the leading blockchain-native capital marketplace for the origination, funding, sale and trading of on-chain loan products and tokenized assets, today announced that it will participate in two upcoming investor conferences, both to be held on Wednesday, December 10, 2025. Chief Executive Officer Michael Tannenbaum will participate in a fireside chat at the Goldman Sachs 2025 Financial Services Conference in New Yor ...

NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Japan Smaller Capitalization Fund, Inc. (the “Fund”) (NYSE: JOF) today declared monthly cash distributions to common shareholders pursuant to its Level Distribution Plan (“LDP”) as follows: Record DateEx-Dividend DatePayment DateDistribution AmountJanuary 15, 2026January 15, 2026January 30, 2026$0.0887February 16, 2026<td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-al ...

Core Insights - Supernus Pharmaceuticals, Inc. is participating in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, where CEO Jack A. Khattar will engage in a fireside chat [1][2] Company Overview - Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases [3][4] - The company's diverse neuroscience portfolio includes approved treatments for ADHD, dyskinesia in Parkinson's disease, hypomobility in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia, and chronic sialorrhea [4]

Core Viewpoint - RYVYL Inc. has received provisional approval for a derivative settlement related to lawsuits against its current and former officers and directors, with a final settlement hearing scheduled [1]. Group 1: Legal Proceedings - On November 14, 2025, District Judge Gonzalo P. Curiel granted provisional approval of the derivative settlement in the case "Christy Hertel, derivatively on behalf of RYVYL Inc. v. Ben Errez et. al." [1] - The derivative lawsuit was filed on June 22, 2023, against certain current and/or former officers and directors of RYVYL [1]. - The proposed settlement also resolves related derivative litigation pending in the Eighth Judicial District Court in Clark County, Nevada [1]. Group 2: Regulatory Filings - The Notice of Proposed Settlement and the Stipulation and Agreement of Settlement have been filed with the U.S. Securities and Exchange Commission as exhibits to the Company's Form 8-K dated November 21, 2025 [2]. - These documents are accessible on the Company's website under Reports & Filings [2]. Group 3: Company Overview - RYVYL Inc. operates a digital payment processing business that enables global transactions and provides payment solutions for underserved markets [3]. - The company has developed applications that offer an end-to-end suite of turnkey financial products, emphasizing enhanced security, data privacy, identity theft protection, and rapid speed to settlement [3].

Core Viewpoint - Echo IQ, an AI and Medical Technology company, is participating in the Piper Sandler 37th Annual Healthcare Conference, highlighting its engagement with the healthcare investment community [1][2]. Company Overview - Echo IQ utilizes AI-driven technology and proprietary software to enhance decision-making in the field of Cardiology [2]. - The company is headquartered in Sydney, Australia [2]. Event Details - The fireside chat featuring CEO Dustin Haines is scheduled for December 2, 2025, at 12:50 p.m. Eastern Time [1][2]. - The event will be held at the Lotte New York Palace [1].